Regadenoson study in children to test safety and dosing
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests how safe regadenoson is in children and how the body handles it after dosing. It also uses a heart “stress test” with MRI (CMR) when doctors feel it’s needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is an eligible age group: 12–17, 2–11, or 1–23 months
- Your child weighs at least 3 kg
- Doctors plan to do a medicine-based heart stress MRI (CMR) for care-related reasons
- Your child’s medicines must be stable for at least 7 days before the study medicine
- If your child can become pregnant: a negative urine pregnancy test and reliable birth control for at least 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of stent (a small mesh tube) that slowly releases a medicine called sirolimus to keep your heart artery open after angioplasty. It is designed for people with narrowing in their heart arteries who need a stent.
This study tests a new kind of coronary stent that slowly releases rapamycin to keep an artery open. You may be invited if you have a small number of specific, treatable blockages and can take the required blood-thinning medicines.
This study looks at people whose coronary artery disease worsens quickly despite standard treatment. It compares them to those with stable disease to understand differences and improve care.
This trial compares two strategies for deciding which heart blockages to treat, using special pressure and blood-flow measurements during a heart procedure. It may help doctors choose more accurate treatment by tailoring the plan to each person’s heart blood flow.
This study tests an experimental drug (RO7763505) in healthy people and people with stable heart disease. It aims to see how safe the drug is and how it works in the body.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
Hear when a new Myocardial Ischemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.